- Home
- Publications
- Publication Search
- Publication Details
Title
Siglecs as Therapeutic Targets in Cancer
Authors
Keywords
-
Journal
Biology-Basel
Volume 10, Issue 11, Pages 1178
Publisher
MDPI AG
Online
2021-11-15
DOI
10.3390/biology10111178
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sialic acid-binding immunoglobulin-like lectin-15 expression on peritumoral macrophages is a favorable prognostic factor for primary central nervous system lymphoma patients
- (2021) Hirotaka Fudaba et al. Scientific Reports
- The Paired Siglecs in Brain Tumours Therapy: The Immunomodulatory Effect of Dexamethasone and Temozolomide in Human Glioma In Vitro Model
- (2021) Przemyslaw Wielgat et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Siglec-6 is a target for chimeric antigen receptor T-cell treatment of chronic lymphocytic leukemia
- (2021) Damian Kovalovsky et al. LEUKEMIA
- Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9
- (2021) Ernesto Rodriguez et al. Nature Communications
- Activating Mutation of SHP2 Establishes a Tumorigenic Phonotype Through Cell-Autonomous and Non-Cell-Autonomous Mechanisms
- (2021) Lei Dong et al. Frontiers in Cell and Developmental Biology
- Combination of CD19 and CD22 CAR‐T cell therapy in relapsed B‐cell acute lymphoblastic leukemia after allogeneic transplantation
- (2021) Shuangyou Liu et al. AMERICAN JOURNAL OF HEMATOLOGY
- Characterization of Cell-Bound CA125 on Immune Cell Subtypes of Ovarian Cancer Patients Using a Novel Imaging Platform
- (2021) Germán González et al. Cancers
- CD169 Expression on Lymph Node Macrophages Predicts in Patients With Gastric Cancer
- (2021) Keiichiro Kumamoto et al. Frontiers in Oncology
- Characterization of HLH-Like Manifestations as a CRS Variant in Patients Receiving CD22 CAR T-Cells
- (2021) Daniel A Lichtenstein et al. BLOOD
- Siglec‐15 promotes the migration of liver cancer cells by repressing lysosomal degradation of CD44
- (2021) Weitao Liu et al. FEBS LETTERS
- Highly accurate protein structure prediction with AlphaFold
- (2021) John Jumper et al. NATURE
- CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
- (2021) Jay Y. Spiegel et al. NATURE MEDICINE
- Consequences of hemophagocytic lymphohistiocytosis‐like cytokine release syndrome toxicities and concurrent bacteremia
- (2021) Katherine E. Masih et al. PEDIATRIC BLOOD & CANCER
- Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity
- (2021) Itziar Ibarlucea-Benitez et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study
- (2021) Guoqing Wei et al. Cancer Immunology Research
- Modulation of Siglec-7 Signaling Via In Situ-Created High-Affinity cis-Ligands
- (2021) Senlian Hong et al. ACS Central Science
- Antibody–Drug Conjugates for the Treatment of Acute Pediatric Leukemia
- (2021) Jamie L. Stokke et al. Journal of Clinical Medicine
- CD33 Expression and Gentuzumab Ozogamicin in Acute Myeloid Leukemia: Two Sides of the Same Coin
- (2021) Matteo Molica et al. Cancers
- Soluble SIGLEC5: A New Prognosis Marker in Colorectal Cancer Patients
- (2021) Karla Montalbán-Hernández et al. Cancers
- Siglec-15 Promotes Tumor Progression in Osteosarcoma via DUSP1/MAPK Pathway
- (2021) Meng-ke Fan et al. Frontiers in Oncology
- Strategy for Leukemia Treatment Targeting SHP-1,2 and SHIP
- (2021) Fang Hao et al. Frontiers in Cell and Developmental Biology
- Siglec-6 as a New Potential Immune Checkpoint for Bladder Cancer Patients
- (2021) Sulayman Benmerzoug et al. European Urology Focus
- Blocking siglec-10hi tumor-associated macrophages improves anti-tumor immunity and enhances immunotherapy for hepatocellular carcinoma
- (2021) Nan Xiao et al. Experimental Hematology & Oncology
- Siglecs as Immune Cell Checkpoints in Disease
- (2020) Shiteng Duan et al. Annual Review of Immunology
- Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
- (2020) Marion Subklewe et al. BLOOD
- Siglec-10 expression is up-regulated in activated human CD4+ T cells
- (2020) E. Bandala-Sanchez et al. HUMAN IMMUNOLOGY
- Eosinophil and mast cell Siglecs: From biology to drug target
- (2020) Jeremy A. O'Sullivan et al. JOURNAL OF LEUKOCYTE BIOLOGY
- CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for Inotuzumab Therapy in Adults
- (2020) Francesco Lanza et al. Cancers
- Reduced Siglec‐7 expression on NK cells predicts NK cell dysfunction in primary hepatocellular carcinoma
- (2020) L. Tao et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed/refractory acute myeloid leukemia (R/R AML).
- (2020) Farhad Ravandi et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting glycosylated antigens on cancer cells using siglec‐7/9‐based CAR T‐cells
- (2020) Sara Meril et al. MOLECULAR CARCINOGENESIS
- Discovery of a new sialic acid binding region that regulates Siglec-7
- (2020) Nao Yamakawa et al. Scientific Reports
- The Roles of Siglec7 and Siglec9 on Natural Killer Cells in Virus Infection and Tumour Progression
- (2020) Yayun Zheng et al. Journal of Immunology Research
- Dual specific CD19/CD22‑targeted chimeric antigen receptor T‑cell therapy for refractory diffuse large B‑cell lymphoma: A case report
- (2020) Chen Huang et al. Oncology Letters
- A Novel Siglec-4 Derived Spacer Improves the Functionality of CAR T Cells Against Membrane-Proximal Epitopes
- (2020) Daniel Schäfer et al. Frontiers in Immunology
- Siglec-15 as an emerging target for next-generation cancer immunotherapy
- (2020) Jingwei Sun et al. CLINICAL CANCER RESEARCH
- Anti–Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis
- (2020) Evan S. Dellon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy
- (2020) Natalia Rodrigues Mantuano et al. Journal for ImmunoTherapy of Cancer
- Glycoengineering of NK Cells with Glycan Ligands of CD22 and Selectins for B‐Cell Lymphoma Therapy
- (2020) Senlian Hong et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- CD33 directed bispecific antibodies in acute myeloid leukemia
- (2020) Mary C. Clark et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Monoclonal IgM and neuropathy: not always anti-MAG
- (2020) Arnaud Jaccard BLOOD
- Liposomal doxorubicin as targeted delivery platform: Current trends in surface functionalization
- (2020) Vivek Makwana et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- 225Ac‐labeled CD33‐targeting antibody reverses resistance to Bcl‐2 inhibitor venetoclax in acute myeloid leukemia models
- (2020) Ravendra Garg et al. Cancer Medicine
- Cancer stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: Challenges and prospects
- (2020) Javad Masoumi et al. Acta Pharmaceutica Sinica B
- Chimeric Antigen Receptor (CAR)-Modified Immune Effector Cell Therapy for Acute Myeloid Leukemia (AML)
- (2020) Utkarsh H. Acharya et al. Cancers
- Current Status on Therapeutic Molecules Targeting Siglec Receptors
- (2020) María Pia Lenza et al. Cells
- Discovery, Function, and Therapeutic Targeting of Siglec-8
- (2020) Bradford A. Youngblood et al. Cells
- Inactivation of the tyrosine phosphatase SHP-2 drives vascular dysfunction in Sepsis
- (2019) Yvonn Heun et al. EBioMedicine
- Human tumor-associated monocytes/macrophages and their regulation of T cell responses in early-stage lung cancer
- (2019) Sunil Singhal et al. Science Translational Medicine
- Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy
- (2019) Jun Wang et al. NATURE MEDICINE
- Bispecific Antibodies in the Treatment of Hematologic Malignancies
- (2019) Johannes Duell et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia
- (2019) Jing Pan et al. LEUKEMIA
- A review of bispecific antibodies and antibody constructs in oncology and clinical challenges
- (2019) Frans V. Suurs et al. PHARMACOLOGY & THERAPEUTICS
- Siglec-9 Regulates an Effector Memory CD8+ T-cell Subset That Congregates in the Melanoma Tumor Microenvironment
- (2019) Quentin Haas et al. Cancer Immunology Research
- Combination of CTLA-4 and PD-1 blockers for treatment of cancer
- (2019) Anand Rotte JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy
- (2019) Amira A. Barkal et al. NATURE
- Sugar Free: Novel Immunotherapeutic Approaches Targeting Siglecs and Sialic Acids to Enhance Natural Killer Cell Cytotoxicity Against Cancer
- (2019) John Daly et al. Frontiers in Immunology
- Malignant ascite-derived extracellular vesicles inhibit T cell activity by upregulating Siglec-10 expression
- (2019) Yujuan Li et al. Cancer Management and Research
- Sialic acid–binding immunoglobulin-like lectins (Siglecs) detect self-associated molecular patterns to regulate immune responses
- (2019) Heinz Läubli et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- The sialoglycan-Siglec glyco-immune checkpoint – a target for improving innate and adaptive anti-cancer immunity
- (2019) Anne Bärenwaldt et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Regulation of peripheral and central immunity: Understanding the role of Src homology 2 domain-containing tyrosine phosphatases, SHP-1 & SHP-2
- (2019) Manika Garg et al. IMMUNOBIOLOGY
- Siglecs in Brain Function and Neurological Disorders
- (2019) Shoib Sarwar Siddiqui et al. Cells
- Terminating the renewal of tumor-associated macrophages: A sialic acid-based targeted delivery strategy for cancer immunotherapy
- (2019) Junqiang Ding et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Contextualizing the Use of Moxetumomab Pasudotox in the Treatment of Relapsed or Refractory Hairy Cell Leukemia
- (2019) Robert J. Kreitman et al. ONCOLOGIST
- SHP-2 in Lymphocytes' Cytokine and Inhibitory Receptor Signaling
- (2019) Charlène Niogret et al. Frontiers in Immunology
- Breast cancer cells promote CD169+ macrophage-associated immunosuppression through JAK2-mediated PD-L1 upregulation on macrophages
- (2019) Weiqiang Jing et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Siglec-14 Enhances NLRP3-Inflammasome Activation in Macrophages
- (2019) Chih-Ming Tsai et al. Journal of Innate Immunity
- Siglec1-expressing subcapsular sinus macrophages provide soil for melanoma lymph node metastasis
- (2019) Rohit Singh et al. eLife
- CD169-positive sinus macrophages in the lymph nodes determine bladder cancer prognosis
- (2018) Touko Asano et al. CANCER SCIENCE
- An Anti-CLL-1 Antibody-Drug Conjugate for the Treatment of Acute Myeloid Leukemia
- (2018) Bing Zheng et al. CLINICAL CANCER RESEARCH
- Targeting Neutrophils in Severe Asthma via Siglec-9
- (2018) Zi Chen et al. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY
- Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
- (2018) Robert J. Kreitman et al. LEUKEMIA
- Targeting SHP-1, 2 and SHIP Pathways: A Novel Strategy for Cancer Treatment?
- (2018) Wolfram C.M. Dempke et al. ONCOLOGY
- CD52 glycan binds the proinflammatory B box of HMGB1 to engage the Siglec-10 receptor and suppress human T cell function
- (2018) Esther Bandala-Sanchez et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cell-based glycan arrays for probing glycan–glycan binding protein interactions
- (2018) Jennie Grace Briard et al. Nature Communications
- Functional CD169 on Macrophages Mediates Interaction with Dendritic Cells for CD8 + T Cell Cross-Priming
- (2018) Dieke van Dinther et al. Cell Reports
- Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells
- (2018) Michal A. Stanczak et al. JOURNAL OF CLINICAL INVESTIGATION
- Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
- (2018) Deepa Bhojwani et al. LEUKEMIA
- Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia
- (2018) Luca Bertamini et al. BMC CANCER
- Soluble Siglec-14 glycan-recognition protein is generated by alternative splicing and suppresses myeloid inflammatory responses
- (2018) Po-Chun Jimmy Huang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- B Cell Siglecs–News on Signaling and Its Interplay With Ligand Binding
- (2018) Sarah J. Meyer et al. Frontiers in Immunology
- Modulation of Immune Tolerance via Siglec-Sialic Acid Interactions
- (2018) Joyce Lübbers et al. Frontiers in Immunology
- Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia
- (2017) Swapna Thota et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Siglec-8 and Siglec-9 binding specificities and endogenous airway ligand distributions and properties
- (2017) Huifeng Yu et al. GLYCOBIOLOGY
- Siglec-7 expression is reduced on a natural killer (NK) cell subset of obese humans
- (2017) Philip Rosenstock et al. IMMUNOLOGIC RESEARCH
- Viewing Siglecs through the lens of tumor immunology
- (2017) Isabella Fraschilla et al. IMMUNOLOGICAL REVIEWS
- Targeted delivery of epirubicin to tumor-associated macrophages by sialic acid-cholesterol conjugate modified liposomes with improved antitumor activity
- (2017) Songlei Zhou et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- The Alzheimer's disease–protective CD33 splice variant mediates adaptive loss of function via diversion to an intracellular pool
- (2017) Shoib S. Siddiqui et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
- (2017) Sydney R. Gordon et al. NATURE
- CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
- (2017) Terry J Fry et al. NATURE MEDICINE
- Research Highlights
- (2017) Fadi Issa TRANSPLANTATION
- Enhancement of Siglec-8 expression predicts adverse prognosis in patients with clear cell renal cell carcinoma
- (2017) Chenzhang Ou et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Resistance to checkpoint blockade therapy through inactivation of antigen presentation
- (2017) Moshe Sade-Feldman et al. Nature Communications
- Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy
- (2016) R. Gardner et al. BLOOD
- Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia
- (2016) U. Reusch et al. CLINICAL CANCER RESEARCH
- Shp2 Deficiency Impairs the Inflammatory Response AgainstHaemophilus influenzaeby Regulating Macrophage Polarization
- (2016) Lifang Zhao et al. JOURNAL OF INFECTIOUS DISEASES
- CD169 identifies an anti-tumour macrophage subpopulation in human hepatocellular carcinoma
- (2016) Yi Zhang et al. JOURNAL OF PATHOLOGY
- Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
- (2016) Hagop M. Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Structural basis for sulfation-dependent self-glycan recognition by the human immune-inhibitory receptor Siglec-8
- (2016) Johannes M. Pröpster et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Sialic Acid Mimetics to Target the Sialic Acid–Siglec Axis
- (2016) Christian Büll et al. TRENDS IN BIOCHEMICAL SCIENCES
- Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts
- (2016) M Cartellieri et al. Blood Cancer Journal
- Classification of Advanced Human Cancers Based on Tumor Immunity in the MicroEnvironment (TIME) for Cancer Immunotherapy
- (2016) Yu Zhang et al. JAMA Oncology
- Soluble Siglec-5 associates to PSGL-1 and displays anti-inflammatory activity
- (2016) Marion Pepin et al. Scientific Reports
- SHP2 sails from physiology to pathology
- (2015) Mylène Tajan et al. European Journal of Medical Genetics
- Sialic acids in cancer biology and immunity
- (2015) Oliver M T Pearce et al. GLYCOBIOLOGY
- Siglec-10 is associated with survival and natural killer cell dysfunction in hepatocellular carcinoma
- (2015) Pei Zhang et al. JOURNAL OF SURGICAL RESEARCH
- Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism
- (2015) C Krupka et al. LEUKEMIA
- Binding specificity of anti-HNK-1 IgM M-protein in anti-MAG neuropathy: Possible clinical relevance
- (2015) Yukihiro Hamada et al. NEUROSCIENCE RESEARCH
- Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis
- (2015) Severa Bunda et al. Nature Communications
- Prognostic Significance of CD169+ Lymph Node Sinus Macrophages in Patients with Malignant Melanoma
- (2015) Y. Saito et al. Cancer Immunology Research
- Much More than M1 and M2 Macrophages, There are also CD169+ and TCR+ Macrophages
- (2015) Leslie Chávez-Galán et al. Frontiers in Immunology
- β2-Microglobulin-mediated Signaling as a Target for Cancer Therapy
- (2014) Takeo Nomura et al. Anti-Cancer Agents in Medicinal Chemistry
- A soluble form of Siglec-9 provides an antitumor benefit against mammary tumor cells expressing MUC1 in transgenic mice
- (2014) Yukiko Tomioka et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- The anticancer efficacy of pixantrone-loaded liposomes decorated with sialic acid–octadecylamine conjugate
- (2014) Zhennan She et al. BIOMATERIALS
- A Reevaluation of CD22 Expression in Human Lung Cancer
- (2014) L. M. Pop et al. CANCER RESEARCH
- The role of CD33 as therapeutic target in acute myeloid leukemia
- (2014) Roland B Walter EXPERT OPINION ON THERAPEUTIC TARGETS
- Siglec functions of microglia
- (2014) B. Linnartz-Gerlach et al. GLYCOBIOLOGY
- Protein-tyrosine Phosphatase Shp2 Positively Regulates Macrophage Oxidative Burst
- (2014) Xing Jun Li et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Interactions between Siglec-7/9 receptors and ligands influence NK cell–dependent tumor immunosurveillance
- (2014) Camilla Jandus et al. JOURNAL OF CLINICAL INVESTIGATION
- Siglec-5 and Siglec-14 are polymorphic paired receptors that modulate neutrophil and amnion signaling responses to group BStreptococcus
- (2014) Syed Raza Ali et al. JOURNAL OF EXPERIMENTAL MEDICINE
- New antibody approaches to lymphoma therapy
- (2014) Tejas Suresh et al. Journal of Hematology & Oncology
- The Role of the Syk/Shp-1 Kinase-Phosphatase Equilibrium in B Cell Development and Signaling
- (2014) A. Alsadeq et al. JOURNAL OF IMMUNOLOGY
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer
- (2014) Heinz Läubli et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer--Letter
- (2013) L. Radvanyi et al. CLINICAL CANCER RESEARCH
- Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab
- (2013) Luis Fayad et al. JOURNAL OF CLINICAL ONCOLOGY
- Expression and Clinical Significance of SHP2 in Gastric Cancer
- (2013) S Dong et al. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
- T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10
- (2013) Esther Bandala-Sanchez et al. NATURE IMMUNOLOGY
- Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
- (2012) W. Haso et al. BLOOD
- The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF- secretion from monocytes/macrophages through the DAP12-Syk pathway
- (2012) R. Takamiya et al. GLYCOBIOLOGY
- Evolution of Siglec-11 and Siglec-16 Genes in Hominins
- (2012) Xiaoxia Wang et al. MOLECULAR BIOLOGY AND EVOLUTION
- Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production
- (2012) M. K. Gleason et al. MOLECULAR CANCER THERAPEUTICS
- Protein tyrosine phosphatases in lymphocyte activation and autoimmunity
- (2012) Inmoo Rhee et al. NATURE IMMUNOLOGY
- Engagement of Siglec-7 Receptor Induces a Pro-Inflammatory Response Selectively in Monocytes
- (2012) Stefania Varchetta et al. PLoS One
- Specific inactivation of two immunomodulatory SIGLEC genes during human evolution
- (2012) X. Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short stature
- (2012) A. D. R. Serra-Nedelec et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PI3K-PKB/Akt Pathway
- (2012) B. A. Hemmings et al. Cold Spring Harbor Perspectives in Biology
- Regulation of B Cell Functions by the Sialic Acid-Binding Receptors Siglec-G and CD22
- (2012) Julia Jellusova et al. Frontiers in Immunology
- Targeting Siglecs—A novel pharmacological strategy for immuno- and glycotherapy
- (2011) Camilla Jandus et al. BIOCHEMICAL PHARMACOLOGY
- Expression of Siglec-11 by human and chimpanzee ovarian stromal cells, with uniquely human ligands: implications for human ovarian physiology and pathology
- (2011) X. Wang et al. GLYCOBIOLOGY
- SIGLEC12, a Human-specific Segregating (Pseudo)gene, Encodes a Signaling Molecule Expressed in Prostate Carcinomas
- (2011) Nivedita Mitra et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells
- (2011) J F de Vries et al. LEUKEMIA
- CD52 as a molecular target for immunotherapy to treat acute myeloid leukemia with high EVI1 expression
- (2011) Y Saito et al. LEUKEMIA
- Targeting B lymphoma with nanoparticles bearing glycan ligands of CD22
- (2011) Weihsu C. Chen et al. LEUKEMIA & LYMPHOMA
- Amelioration of sepsis by inhibiting sialidase-mediated disruption of the CD24-SiglecG interaction
- (2011) Guo-Yun Chen et al. NATURE BIOTECHNOLOGY
- Mast Cell Accumulation in Glioblastoma with a Potential Role for Stem Cell Factor and Chemokine CXCL12
- (2011) Jelena Põlajeva et al. PLoS One
- In vivo targeting of B-cell lymphoma with glycan ligands of CD22
- (2010) W. C. Chen et al. BLOOD
- Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study
- (2010) Anjali Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- SHP-1 in T Cells Limits the Production of CD8 Effector Cells without Impacting the Formation of Long-Lived Central Memory Cells
- (2010) C. C. Fowler et al. JOURNAL OF IMMUNOLOGY
- CD22 Is a Recycling Receptor That Can Shuttle Cargo between the Cell Surface and Endosomal Compartments of B Cells
- (2010) M. K. O'Reilly et al. JOURNAL OF IMMUNOLOGY
- Protein tyrosine phosphatase SHP-1 positively regulates TLR-induced IL-12p40 production in macrophages through inhibition of phosphatidylinositol 3-kinase
- (2010) Delu Zhou et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Alleviation of Neurotoxicity by Microglial Human Siglec-11
- (2010) Y. Wang et al. JOURNAL OF NEUROSCIENCE
- CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells
- (2009) Ravindra Majeti et al. CELL
- Deletion polymorphism of SIGLEC14 and its functional implications
- (2009) M. Yamanaka et al. GLYCOBIOLOGY
- The structure, regulation, and function of ZAP-70
- (2009) Byron B. Au-Yeung et al. IMMUNOLOGICAL REVIEWS
- Siglec receptors and hiding plaques in Alzheimer's disease
- (2009) Antero Salminen et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- CD24 and Siglec-10 Selectively Repress Tissue Damage-Induced Immune Responses
- (2009) G.-Y. Chen et al. SCIENCE
- CD24-Siglec G/10 discriminates danger- from pathogen-associated molecular patterns
- (2009) Yang Liu et al. TRENDS IN IMMUNOLOGY
- SIGLEC16encodes a DAP12-associated receptor expressed in macrophages that evolved from its inhibitory counterpartSIGLEC11and has functional and non-functional alleles in humans
- (2008) Huan Cao et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Complement and cellular cytotoxicity in antibody therapy of cancer
- (2008) Siao-Yi Wang et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- DAP10- and DAP12-associated receptors in innate immunity
- (2008) Lewis L. Lanier IMMUNOLOGICAL REVIEWS
- Immune escape as a fundamental trait of cancer: focus on IDO
- (2008) G C Prendergast ONCOGENE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now